Skip to content

Debt-to-equity at other companies

Vericel logo
VericelVCEL
0.3×-0.1×
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
0.6×0.0×
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
0.6×+0.2×
Bioventus logo
BioventusBVS
1.5×-0.9×
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
0.3×-0.2×
Globus Medical logo
Globus MedicalGMED
0.0×

Other financials

Income statement

See full
Revenue$29.6M+13.2%
Net income-$5.1M-3.8%

Balance sheet

See full
Cash & equivalents$41.0M-23.1%
Total debt$25.7M+1.2%
Total equity$133.9M-9.8%
Total assets$179.4M-5.9%

Cash flow

See full
Operating cash flow-$4.8M-3,628%
CapEx$1.4M-49.3%
Free cash flow-$6.3M-112%

Valuation

See full
Market cap$204.37M+31.6%
Enterprise value$189.09M+48.7%
P/S1.8×+0.1×

Profitability

See full
Net margin-9.8%-4.4pp
FCF margin0.9%

Returns & leverage

See full
Return on equity-8%-3.4pp
Current ratio4.5×-1.3×

Where this comes from

Calculated from Anika Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Anika Therapeutics's debt-to-equity?
Anika Therapeutics (ANIK) reported debt-to-equity of 0.2× in Q1 2026.
How has Anika Therapeutics's debt-to-equity changed year-over-year?
Anika Therapeutics's debt-to-equity increased by 12.1% year-over-year, from 0.2× to 0.2×.
What is the long-term trend for Anika Therapeutics's debt-to-equity?
Over 5 years (2020 to 2025), Anika Therapeutics's debt-to-equity has grown at a 17.4% compound annual growth rate (CAGR), from 0.1× to 0.2×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.